STEVE ELMS
CIK 1250195 · last filed 2026-03-09
STEVE ELMS is a corporate insider who has filed 59 SEC Form 4 insider transactions across 9 companies since 2008. The most recent filing shows the insider bought $217.4K of ADMA on Mar 9, 2026. Across all open-market trades the lifetime net is +$6.1M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $19.2M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$19.17M
9
59
$6.06M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ADMA | Director | 2,136,750 | $8.79 | $18.78M | -$17.76M | 19 | 2026-03-09 |
| MRKR | Director | 328,338 | $1.18 | $387.4K | $2.04M | 8 | 2025-11-19 |
| Elevation Oncology, Inc. (ELEV) Delisted | Director | — | $0.36 | — | $0 | 3 | 2025-07-24 |
| Zosano Pharma Corp (ZSAN) Delisted | Director | 78,307 | $0.56 | $43.7K | $0 | 5 | 2021-06-14 |
| Loxo Oncology, Inc. (LOXO) Delisted | Director | 5,570,102 | — | — | $18.42M | 8 | 2019-02-15 |
| PERNIX THERAPEUTICS HOLDINGS, INC. (PTX) Delisted | Director | 201,000 | — | — | $0 | 4 | 2016-05-31 |
| Cidara Therapeutics, Inc. (CDTX) Delisted | Director | 35,155 | $221.38 | $7.78M | $0 | 1 | 2015-04-22 |
| AMBIT BIOSCIENCES CORP (AMBI) Delisted | Director | 1,650,156 | $0.54 | $890.4K | $3.39M | 3 | 2014-09-04 |
| MAPP | Director | 0 | $27.00 | $0 | -$33.8K | 5 | 2010-05-24 |
Recent Filings
59 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-03-09 | ADMA | Buy (P) | +14,000 | $217.4K | EDGAR |
| 2026-02-11 | ADMA | Grant (A) | +10,690 | $0 | EDGAR |
| 2025-11-19 | MRKR | Grant (A) | — | $0 | EDGAR |
| 2025-07-24 | Elevation Oncology, Inc. (ELEV) Delisted | Disp (D) | — | $0 | EDGAR |
| 2025-06-16 | ADMA | Mixed | −92,941 | -$7.69M | EDGAR |
| 2025-06-12 | ADMA | Notice (144) | −425,621 | -$9.31M | EDGAR |
| 2025-06-09 | Elevation Oncology, Inc. (ELEV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-02-21 | ADMA | Grant (A) | +10,889 | $0 | EDGAR |
| 2025-02-14 | MRKR | Grant (A) | — | $0 | EDGAR |
| 2024-12-26 | MRKR | Buy (P) | +11,085 | $35.5K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.